Hearing assesment in children after intrauterine exposure to platinum-based treatment of pregnant cancer patients: A study from the International Network on Cancer, Infertility and Pregnancy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F25%3A43928937" target="_blank" >RIV/00064173:_____/25:43928937 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/25:43928937
Result on the web
<a href="https://doi.org/10.1186/s12887-025-05992-z" target="_blank" >https://doi.org/10.1186/s12887-025-05992-z</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s12887-025-05992-z" target="_blank" >10.1186/s12887-025-05992-z</a>
Alternative languages
Result language
angličtina
Original language name
Hearing assesment in children after intrauterine exposure to platinum-based treatment of pregnant cancer patients: A study from the International Network on Cancer, Infertility and Pregnancy
Original language description
BACKGROUND: Literature on the effects of prenatal exposure to platinum-based chemotherapy on the auditory capacity of the offspring is scarce. The current study aims to describe the occurrence of hearing impairment in a well-documented series of children who underwent audiological testing. METHODS: An international, descriptive multicentre study using oncological, obstetrical, and neonatal data registered by the International Network of Cancer Infertility and Pregnancy database, was performed. The offspring (aged >= 4 years) underwent pure tone audiometry. Audiological outcomes were registered after expert review, using international standardized audiological grading as developed for platinum exposed childhood cancer patients: the Muenster criteria and the International Society for Paediatric Oncology classification. Platinum-induced hearing loss was defined as bilateral hearing loss, starting at 8 kHz and without middle ear problems confirmed by tympanometry or otoscopy. FINDINGS: Twenty-five children were included of which 17 children (68%) had been exposed to cisplatin and 8 (32%) to carboplatin, none to both. Median gestational age at start maternal treatment was 22 weeks (range, 14-31). Median gestational age at delivery was 35 weeks (range, 31-39), and median birth weight was 2345 g (range, 1526-3360). Neonatal hearing screening, performed in 10 children (40%), showed no hearing loss. At a median age of 6.0 years (range, 4.0-28(.)0), 6 children (24%) revealed bilateral hearing loss, using cut-off values of Muenster grade >= 2b and SIOP grade >= 2. INTERPRETATION: Antenatal exposure to platinum-based chemotherapy is associated with hearing loss in a subset of the offspring. Prospective longitudinal standardized surveillance of auditory function is advised, starting after birth. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-025-05992-z.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30214 - Obstetrics and gynaecology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BMC Pediatrics
ISSN
1471-2431
e-ISSN
1471-2431
Volume of the periodical
25
Issue of the periodical within the volume
October
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
703
UT code for WoS article
001586849300049
EID of the result in the Scopus database
2-s2.0-105017817780